Medical Care

Global Gram-positive Bacterial Infections Market Research Report 2025

The global market for Gram-positive Bacterial Infections was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Gram-positive Bacterial Infections is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gram-positive Bacterial Infections is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Gram-positive Bacterial Infections in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Gram-positive Bacterial Infections include GlaxoSmithKline, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., AstraZeneca, Astellas Pharma Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Cipla, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gram-positive Bacterial Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gram-positive Bacterial Infections.
The Gram-positive Bacterial Infections market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gram-positive Bacterial Infections market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gram-positive Bacterial Infections companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Johnson & Johnson Inc.
Merck & Co. Inc.
Pfizer Inc.
AstraZeneca
Astellas Pharma Inc.
Novartis AG
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Cipla
Segment by Type
B-Lactam Antimicrobials
Fluoroquinolones
Penicillin
Cephalosporins
RNA Immunoprecipitation (RIP)
Vaccine
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gram-positive Bacterial Infections company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gram-positive Bacterial Infections Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 B-Lactam Antimicrobials
1.2.3 Fluoroquinolones
1.2.4 Penicillin
1.2.5 Cephalosporins
1.2.6 RNA Immunoprecipitation (RIP)
1.2.7 Vaccine
1.2.8 Other
1.3 Market by Application
1.3.1 Global Gram-positive Bacterial Infections Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gram-positive Bacterial Infections Market Perspective (2020-2031)
2.2 Global Gram-positive Bacterial Infections Growth Trends by Region
2.2.1 Global Gram-positive Bacterial Infections Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gram-positive Bacterial Infections Historic Market Size by Region (2020-2025)
2.2.3 Gram-positive Bacterial Infections Forecasted Market Size by Region (2026-2031)
2.3 Gram-positive Bacterial Infections Market Dynamics
2.3.1 Gram-positive Bacterial Infections Industry Trends
2.3.2 Gram-positive Bacterial Infections Market Drivers
2.3.3 Gram-positive Bacterial Infections Market Challenges
2.3.4 Gram-positive Bacterial Infections Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gram-positive Bacterial Infections Players by Revenue
3.1.1 Global Top Gram-positive Bacterial Infections Players by Revenue (2020-2025)
3.1.2 Global Gram-positive Bacterial Infections Revenue Market Share by Players (2020-2025)
3.2 Global Gram-positive Bacterial Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gram-positive Bacterial Infections Revenue
3.4 Global Gram-positive Bacterial Infections Market Concentration Ratio
3.4.1 Global Gram-positive Bacterial Infections Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gram-positive Bacterial Infections Revenue in 2024
3.5 Global Key Players of Gram-positive Bacterial Infections Head office and Area Served
3.6 Global Key Players of Gram-positive Bacterial Infections, Product and Application
3.7 Global Key Players of Gram-positive Bacterial Infections, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gram-positive Bacterial Infections Breakdown Data by Type
4.1 Global Gram-positive Bacterial Infections Historic Market Size by Type (2020-2025)
4.2 Global Gram-positive Bacterial Infections Forecasted Market Size by Type (2026-2031)
5 Gram-positive Bacterial Infections Breakdown Data by Application
5.1 Global Gram-positive Bacterial Infections Historic Market Size by Application (2020-2025)
5.2 Global Gram-positive Bacterial Infections Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gram-positive Bacterial Infections Market Size (2020-2031)
6.2 North America Gram-positive Bacterial Infections Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gram-positive Bacterial Infections Market Size by Country (2020-2025)
6.4 North America Gram-positive Bacterial Infections Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gram-positive Bacterial Infections Market Size (2020-2031)
7.2 Europe Gram-positive Bacterial Infections Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gram-positive Bacterial Infections Market Size by Country (2020-2025)
7.4 Europe Gram-positive Bacterial Infections Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gram-positive Bacterial Infections Market Size (2020-2031)
8.2 Asia-Pacific Gram-positive Bacterial Infections Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2020-2025)
8.4 Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gram-positive Bacterial Infections Market Size (2020-2031)
9.2 Latin America Gram-positive Bacterial Infections Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gram-positive Bacterial Infections Market Size by Country (2020-2025)
9.4 Latin America Gram-positive Bacterial Infections Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gram-positive Bacterial Infections Market Size (2020-2031)
10.2 Middle East & Africa Gram-positive Bacterial Infections Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2020-2025)
10.4 Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Gram-positive Bacterial Infections Introduction
11.1.4 GlaxoSmithKline Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.1.5 GlaxoSmithKline Recent Development
11.2 Johnson & Johnson Inc.
11.2.1 Johnson & Johnson Inc. Company Details
11.2.2 Johnson & Johnson Inc. Business Overview
11.2.3 Johnson & Johnson Inc. Gram-positive Bacterial Infections Introduction
11.2.4 Johnson & Johnson Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.2.5 Johnson & Johnson Inc. Recent Development
11.3 Merck & Co. Inc.
11.3.1 Merck & Co. Inc. Company Details
11.3.2 Merck & Co. Inc. Business Overview
11.3.3 Merck & Co. Inc. Gram-positive Bacterial Infections Introduction
11.3.4 Merck & Co. Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.3.5 Merck & Co. Inc. Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Details
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Gram-positive Bacterial Infections Introduction
11.4.4 Pfizer Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.4.5 Pfizer Inc. Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Gram-positive Bacterial Infections Introduction
11.5.4 AstraZeneca Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.5.5 AstraZeneca Recent Development
11.6 Astellas Pharma Inc.
11.6.1 Astellas Pharma Inc. Company Details
11.6.2 Astellas Pharma Inc. Business Overview
11.6.3 Astellas Pharma Inc. Gram-positive Bacterial Infections Introduction
11.6.4 Astellas Pharma Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.6.5 Astellas Pharma Inc. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Gram-positive Bacterial Infections Introduction
11.7.4 Novartis AG Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Sanofi SA
11.8.1 Sanofi SA Company Details
11.8.2 Sanofi SA Business Overview
11.8.3 Sanofi SA Gram-positive Bacterial Infections Introduction
11.8.4 Sanofi SA Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.8.5 Sanofi SA Recent Development
11.9 Sun Pharmaceutical Industries Ltd.
11.9.1 Sun Pharmaceutical Industries Ltd. Company Details
11.9.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.9.3 Sun Pharmaceutical Industries Ltd. Gram-positive Bacterial Infections Introduction
11.9.4 Sun Pharmaceutical Industries Ltd. Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.9.5 Sun Pharmaceutical Industries Ltd. Recent Development
11.10 Cipla
11.10.1 Cipla Company Details
11.10.2 Cipla Business Overview
11.10.3 Cipla Gram-positive Bacterial Infections Introduction
11.10.4 Cipla Revenue in Gram-positive Bacterial Infections Business (2020-2025)
11.10.5 Cipla Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gram-positive Bacterial Infections Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of B-Lactam Antimicrobials
Table 3. Key Players of Fluoroquinolones
Table 4. Key Players of Penicillin
Table 5. Key Players of Cephalosporins
Table 6. Key Players of RNA Immunoprecipitation (RIP)
Table 7. Key Players of Vaccine
Table 8. Key Players of Other
Table 9. Global Gram-positive Bacterial Infections Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Gram-positive Bacterial Infections Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Gram-positive Bacterial Infections Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Gram-positive Bacterial Infections Market Share by Region (2020-2025)
Table 13. Global Gram-positive Bacterial Infections Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Gram-positive Bacterial Infections Market Share by Region (2026-2031)
Table 15. Gram-positive Bacterial Infections Market Trends
Table 16. Gram-positive Bacterial Infections Market Drivers
Table 17. Gram-positive Bacterial Infections Market Challenges
Table 18. Gram-positive Bacterial Infections Market Restraints
Table 19. Global Gram-positive Bacterial Infections Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Gram-positive Bacterial Infections Market Share by Players (2020-2025)
Table 21. Global Top Gram-positive Bacterial Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-positive Bacterial Infections as of 2024)
Table 22. Ranking of Global Top Gram-positive Bacterial Infections Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Gram-positive Bacterial Infections Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Gram-positive Bacterial Infections, Headquarters and Area Served
Table 25. Global Key Players of Gram-positive Bacterial Infections, Product and Application
Table 26. Global Key Players of Gram-positive Bacterial Infections, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Gram-positive Bacterial Infections Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Gram-positive Bacterial Infections Revenue Market Share by Type (2020-2025)
Table 30. Global Gram-positive Bacterial Infections Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Gram-positive Bacterial Infections Revenue Market Share by Type (2026-2031)
Table 32. Global Gram-positive Bacterial Infections Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Gram-positive Bacterial Infections Revenue Market Share by Application (2020-2025)
Table 34. Global Gram-positive Bacterial Infections Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Gram-positive Bacterial Infections Revenue Market Share by Application (2026-2031)
Table 36. North America Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Gram-positive Bacterial Infections Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Gram-positive Bacterial Infections Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Gram-positive Bacterial Infections Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Gram-positive Bacterial Infections Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Gram-positive Bacterial Infections Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Gram-positive Bacterial Infections Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Gram-positive Bacterial Infections Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2026-2031) & (US$ Million)
Table 51. GlaxoSmithKline Company Details
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Gram-positive Bacterial Infections Product
Table 54. GlaxoSmithKline Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 55. GlaxoSmithKline Recent Development
Table 56. Johnson & Johnson Inc. Company Details
Table 57. Johnson & Johnson Inc. Business Overview
Table 58. Johnson & Johnson Inc. Gram-positive Bacterial Infections Product
Table 59. Johnson & Johnson Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 60. Johnson & Johnson Inc. Recent Development
Table 61. Merck & Co. Inc. Company Details
Table 62. Merck & Co. Inc. Business Overview
Table 63. Merck & Co. Inc. Gram-positive Bacterial Infections Product
Table 64. Merck & Co. Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 65. Merck & Co. Inc. Recent Development
Table 66. Pfizer Inc. Company Details
Table 67. Pfizer Inc. Business Overview
Table 68. Pfizer Inc. Gram-positive Bacterial Infections Product
Table 69. Pfizer Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 70. Pfizer Inc. Recent Development
Table 71. AstraZeneca Company Details
Table 72. AstraZeneca Business Overview
Table 73. AstraZeneca Gram-positive Bacterial Infections Product
Table 74. AstraZeneca Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 75. AstraZeneca Recent Development
Table 76. Astellas Pharma Inc. Company Details
Table 77. Astellas Pharma Inc. Business Overview
Table 78. Astellas Pharma Inc. Gram-positive Bacterial Infections Product
Table 79. Astellas Pharma Inc. Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 80. Astellas Pharma Inc. Recent Development
Table 81. Novartis AG Company Details
Table 82. Novartis AG Business Overview
Table 83. Novartis AG Gram-positive Bacterial Infections Product
Table 84. Novartis AG Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 85. Novartis AG Recent Development
Table 86. Sanofi SA Company Details
Table 87. Sanofi SA Business Overview
Table 88. Sanofi SA Gram-positive Bacterial Infections Product
Table 89. Sanofi SA Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 90. Sanofi SA Recent Development
Table 91. Sun Pharmaceutical Industries Ltd. Company Details
Table 92. Sun Pharmaceutical Industries Ltd. Business Overview
Table 93. Sun Pharmaceutical Industries Ltd. Gram-positive Bacterial Infections Product
Table 94. Sun Pharmaceutical Industries Ltd. Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 95. Sun Pharmaceutical Industries Ltd. Recent Development
Table 96. Cipla Company Details
Table 97. Cipla Business Overview
Table 98. Cipla Gram-positive Bacterial Infections Product
Table 99. Cipla Revenue in Gram-positive Bacterial Infections Business (2020-2025) & (US$ Million)
Table 100. Cipla Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
Table 104. Authors List of This Report


List of Figures
Figure 1. Gram-positive Bacterial Infections Picture
Figure 2. Global Gram-positive Bacterial Infections Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gram-positive Bacterial Infections Market Share by Type: 2024 VS 2031
Figure 4. B-Lactam Antimicrobials Features
Figure 5. Fluoroquinolones Features
Figure 6. Penicillin Features
Figure 7. Cephalosporins Features
Figure 8. RNA Immunoprecipitation (RIP) Features
Figure 9. Vaccine Features
Figure 10. Other Features
Figure 11. Global Gram-positive Bacterial Infections Market Size by Application (2020-2031) & (US$ Million)
Figure 12. Global Gram-positive Bacterial Infections Market Share by Application: 2024 VS 2031
Figure 13. Hospital Case Studies
Figure 14. Clinic Case Studies
Figure 15. Other Case Studies
Figure 16. Gram-positive Bacterial Infections Report Years Considered
Figure 17. Global Gram-positive Bacterial Infections Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Gram-positive Bacterial Infections Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Gram-positive Bacterial Infections Market Share by Region: 2024 VS 2031
Figure 20. Global Gram-positive Bacterial Infections Market Share by Players in 2024
Figure 21. Global Top Gram-positive Bacterial Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-positive Bacterial Infections as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Gram-positive Bacterial Infections Revenue in 2024
Figure 23. North America Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Gram-positive Bacterial Infections Market Share by Country (2020-2031)
Figure 25. United States Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Gram-positive Bacterial Infections Market Share by Country (2020-2031)
Figure 29. Germany Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Gram-positive Bacterial Infections Market Share by Region (2020-2031)
Figure 37. China Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Gram-positive Bacterial Infections Market Share by Country (2020-2031)
Figure 45. Mexico Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Gram-positive Bacterial Infections Market Share by Country (2020-2031)
Figure 49. Turkey Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Gram-positive Bacterial Infections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GlaxoSmithKline Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 53. Johnson & Johnson Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 54. Merck & Co. Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 55. Pfizer Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 56. AstraZeneca Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 57. Astellas Pharma Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 58. Novartis AG Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 59. Sanofi SA Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 60. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 61. Cipla Revenue Growth Rate in Gram-positive Bacterial Infections Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies